Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...
Zacks Investment Research on MSN
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why
Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...
Protagonist Therapeutics (PTGX) shares ended the last trading session 4.7% higher at $101.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million ...
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results